UBS: Presenting Kangde (02359) “Buy” Rating and HK$255.9 Target Price to Advance HI+AI+MI Integration Strategy

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that UBS released a research report stating that it gave Yao Ming Kangde (02359) a “buy” rating and a target price of HK$255.9. Yao Ming Kangde held the 2026 Investor Day event. The management reaffirmed the 2026 revenue guidelines of 61 billion yuan to 61.9 billion yuan, and the adjusted net interest rate is expected to remain stable. The company proposed a vision of integrating human intelligence (HI), artificial intelligence (AI) and machine intelligence (MI), with the aim of further strengthening the CRDMO model.

Yao Ming Kangde emphasized that its market position is still stable. In the “Molecule of the Year” (Molecule of the Year) nomination list, the company provided services for 7 of them. Furthermore, out of the 10 best-selling synthetic drugs in the world in 2025, 4 will be serviced by Pharmacom Kangde.

The company proposes to integrate human intelligence, artificial intelligence and machine intelligence, and combine scientific expertise with algorithms, data, and automated synthesis and testing capabilities. Through this approach, the company will further strengthen the contract research, development and manufacturing organization (CRDMO) model, using both traditional and artificial intelligence-driven drug discovery (AIDD) paths to accelerate early R&D needs, and ultimately create more incremental opportunities in subsequent development and production stages.